Drugs / 21.15.GPC3-CAR T Cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07513194 | Sep 2026 → Oct 2029 expected | atypical teratoid rhabdoid tumor | Baylor College of Medicine | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06198296 | Jun 2025 → Feb 2028 expected | Wilms tumor, hepatoblastoma, liposarcoma, rhabdoid tumor +3 | Baylor College of Medicine | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 21.15.GPC3-CAR T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07513194 ↗ |
| Action | Deplete | “makes them recognize cancer cells and kill them.” NCT06198296 ↗ |
| Modality | Cell therapy | “21.15.GPC3-CAR T cells” NCT06198296 ↗ |
| Route | Other | “administered intracavitarily” NCT07513194 ↗ |
| Target | GPC3 | “a GPC3-specific CAR” NCT07513194 ↗ |